Dr. Robert Gut joined uniQure as Chief Medical Officer in August 2018. Dr. Robert Gut has served as a member of our board since June 2018. Dr. Gut has nearly 20 years of experience in the biopharmaceutical industry leading clinical development and medical affairs activities in hematology and other therapeutic areas.
Dr. Gut most recently served as Chief Medical Officer of Versartis, Inc. until its merger with Aravive Biologics in June 2018. For the majority of his career, Dr. Gut served as Vice President, Clinical Development & Medical Affairs at Novo Nordisk Inc., where he headed the company's U.S. Biopharm Medical organization with leading products in hemophilia, including NovoSeven® (Factor VIIa), NovoEight® (Factor VIII), Tretten® (Factor XIII) and Factor IX. Dr. Gut's contributions helped achieve nine different FDA approvals and the successful launches of those products. He has also served as a member of the Advisory Committees for Reproductive Health Drugs and Drug Safety and Risk Management for the FDA’s Center for Drug Evaluation and Research.
Dr. Gut is responsible for leading all clinical research and development, medical affairs and related functions at uniQure.
Dr. Gut received his Doctor of Medicine degree from the Medical University of Lublin, and his Doctorate degree from Lublin Institute of Medicine, Poland. He attended numerous postgraduate programs at Wharton, Stanford and Harvard Business School.